PHARMING GROUP Stock Euronext Amsterdam
Stocks
NL0000377018
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Euronext Amsterdam
|
||
| - EUR | - |
|
| Aug. 13 | Pharming Launches Joenja in Japan for Adult, Pediatric APDS Patients | MT |
| Aug. 13 | Pharming Group Launches Rare Primary Immunodeficiency Therapy Joenja in Japan | MT |
| Market Cap | 704M 816M 660M 602M 1.13B 78.03B 1.14B 7.83B 3.05B 39.39B 3.07B 3B 131B | P/E 2026 * |
26.8x | P/E 2027 * | 34.4x |
|---|---|---|---|---|---|
| Enterprise Value | 651M 755M 610M 557M 1.05B 72.17B 1.05B 7.24B 2.82B 36.43B 2.84B 2.77B 121B | EV / Sales 2026 * |
1.7x | EV / Sales 2027 * | 1.45x |
| Free-Float |
98.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : PHARMING GROUP
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2025-03-03 | |
Kenneth Lynard
DFI | Director of Finance/CFO | 58 | 2025-09-30 |
Anurag Relan
CTO | Chief Tech/Sci/R&D Officer | 54 | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Barbara Yanni
BRD | Director/Board Member | 71 | 2020-12-10 |
Mark Pykett
BRD | Director/Board Member | 62 | 2020-12-10 |
| Director/Board Member | 60 | 2021-05-18 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.13% | -6.44% | +60.47% | +112.05% | 1,047B | |
| +0.85% | -0.81% | +52.77% | +63.15% | 646B | |
| -1.03% | -3.58% | +22.87% | +73.29% | 451B | |
| -1.46% | -4.50% | +37.43% | +38.41% | 355B | |
| -0.72% | -2.89% | +21.86% | +36.79% | 291B | |
| -1.19% | -2.21% | +1.35% | +12.29% | 252B | |
| -1.05% | -1.57% | +51.40% | +68.55% | 234B | |
| +0.08% | -1.78% | -17.64% | -54.29% | 203B | |
| -2.14% | -0.30% | +29.42% | +89.10% | 181B | |
| Average | -0.77% | -2.68% | +28.88% | +48.82% | 406.59B | |
| Weighted average by Cap. | -0.48% | -3.46% | +38.66% | +65.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 383M 444M 359M 328M 617M 42.46B 619M 4.26B 1.66B 21.43B 1.67B 1.63B 71.07B | 425M 493M 398M 364M 685M 47.12B 687M 4.73B 1.84B 23.79B 1.85B 1.81B 78.87B |
| Net income | 21.04M 24.41M 19.72M 18.01M 33.92M 2.33B 34.03M 234M 91.3M 1.18B 91.66M 89.66M 3.91B | 29.62M 34.37M 27.77M 25.35M 47.75M 3.28B 47.9M 329M 129M 1.66B 129M 126M 5.5B |
| Net Debt | -52.84M -61.32M -49.54M -45.23M -85.2M -5.86B -85.47M -588M -229M -2.96B -230M -225M -9.81B | -86.38M -100M -80.99M -73.94M -139M -9.58B -140M -961M -375M -4.84B -376M -368M -16.04B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
